18 Diabetic Patients Implanted With VeriMed RFID Microchip At Atlanta Diabetes EXPO
At the Diabetes EXPO, physicians implanted VeriMed RFID microchips in conference attendees who signed up for the voluntary procedure. The VeriMed Patient Identification System, which utilizes an implantable RFID microchip in combination with a handheld RFID scanner and a secure patient database, provides immediate access to important health information for patients who arrive at an emergency department unable to communicate.
Scott R. Silverman, Chairman and CEO of VeriChip, commented, "We believe the VeriMed Patient Identification System is an essential health care solution for at-risk patients, including diabetics, who tend to present with various co-morbidities and medications, and are more frequently admitted to emergency departments. Since the inception of the VeriMed System, we always knew that the diabetic community was in need of a way to communicate their medical information better and more frequently. We will continue to focus on diabetics and to enhance our relationship further with the American Diabetes Association. The Atlanta Diabetes EXPO provides us direct access so we can continue to educate an important target audience."
The Diabetes EXPO is a patient-driven tradeshow, including professional speakers and a variety of ADA program/event information, where exhibitors from pharmaceutical and medical device companies display beneficial products for diabetics. The Diabetes EXPO began in 1995 in Phoenix, Arizona, and has grown to 18, metro, major and mid-size cities around the U.S. The next event will be held in Boston on March 17, 2007.
About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. VeriChip sells passive RFID systems for identification purposes and active RFID systems for local-area location and identification purposes. VeriChip recently began to market its VeriMed(TM) Patient Identification System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.
VeriChip Corporation is majority-owned by Applied Digital Inc. (Nasdaq: ADSX), which also owns a majority position in Digital Angel Corporation (Amex: DOC).
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
VeriChip Corporation
http://www.verichipcorp.com
18 pacienþi diabetici VeriMed implanturi cu microcip RFID de la Atlanta, diabet zaharat de EXPO - 18 Diabetic Patients Implanted With VeriMed RFID Microchip At Atlanta Diabetes EXPO - articole medicale engleza - startsanatate